The Global Gene Therapy in CNS Disorder Market represents one of the most exciting and rapidly evolving frontiers in modern medicine. Central nervous system (CNS) disorders, including neurodegenerative diseases like Alzheimer's and Parkinson's, demyelinating conditions like multiple sclerosis, psychiatric disorders, traumatic brain injury, and stroke, have long been considered among the most challenging to treat. The blood-brain barrier, the complexity of neural circuits, and the post-mitotic nature of neurons have all posed formidable obstacles to traditional drug development. Gene therapy offers a fundamentally different approach: rather than managing symptoms, it aims to address the root cause of these diseases by correcting, replacing, or silencing disease-causing genes.

According to the comprehensive report by WiseGuy Reports, the Global Gene Therapy in CNS Disorder Market was valued at approximately $5.8 billion in 2024. This valuation serves as a baseline for what is expected to be a period of extraordinary expansion. The market is projected to grow from $6.7 billion in 2025 to an impressive $25.0 billion by 2035. This growth trajectory represents a compound annual growth rate (CAGR) of 14.2% over the forecast period from 2025 to 2035. In essence, the market is expected to more than quadruple in value within a single decade, underscoring the accelerating adoption of gene-based therapies for neurological conditions.

Several interconnected factors are driving this explosive growth. First and foremost is the increasing prevalence of CNS disorders worldwide. According to the World Health Organization, the global population aged 60 years and older is expected to reach 2.1 billion by 2050, up from 1 billion in 2019. This demographic shift correlates directly with increased incidence of age-related CNS disorders. The Alzheimer's Association estimates that in 2020, there were approximately 5.8 million Americans living with Alzheimer's disease, a number projected to rise to nearly 14 million by 2060. Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis affect millions more globally. This rising prevalence creates urgent demand for innovative treatments that can modify disease progression rather than merely alleviating symptoms.

Second, advancements in gene editing technologies are revolutionizing the field. The development of CRISPR-Cas9 and other genome editing systems has enabled precise modification of genetic material, offering the potential to correct disease-causing mutations at their source. A National Institutes of Health study highlighted that CRISPR technology has already seen successful applications in the laboratory for treating genetic mutations responsible for various CNS disorders. Organizations like the Broad Institute are pursuing research to expand the capabilities of gene editing, leading to better outcomes in the treatment of CNS disorders.

Third, growing investment in research and development is accelerating the pipeline of gene therapies for CNS disorders. The National Institutes of Health's budget for neuroscience research reached over $3 billion for fiscal year 2022 to support innovative projects, including gene therapies. Industry collaborations between academic institutions and biotechnology firms are increasingly common, leveraging expertise to accelerate drug development. The report notes that governments and health organizations are prioritizing gene therapies as solutions for neurodegenerative diseases, providing regulatory support that facilitates faster approvals and market entry.

The market is also being shaped by a noticeable shift towards personalized gene therapies tailored to individual patient profiles, particularly in North America and Europe, where regulations are becoming more favorable for innovative treatment options. The convergence of technology and healthcare, particularly advancements in CRISPR and other gene-editing tools, is fueling interest and investment in the gene therapy sector, making it a vibrant field with the potential for transformative results in the management of CNS disorders.

Regionally, North America leads the market, valued at $3 billion in 2024 and projected to grow substantially to $12 billion by 2035, driven by advanced healthcare infrastructure and robust R&D activities. Europe follows with steady expansion, supported by favorable regulatory frameworks like the European Medicines Agency's adaptive pathways. The Asia-Pacific region is poised for rapid growth, fueled by rising healthcare expenditures, greater adoption of innovative therapies, and supportive government initiatives like Japan's Sakigake Designation System.